当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Rajat Bhende, Muthalib Abdul, Rajesh Kshirsagar, Swapna Patankar, Priyadarshini Banerjee, Ruturaj Deshpande
Aim & Objective: To present the current considerations, natural history and treatment modalities of cutaneous neurofibromas (cNF)
Methods: Cutaneous Neurofibroma experts from various research and clinical backgrounds reviewed the terms currently in use for cNF as well as the clinical, histologic, and radiographic features of these tumors using available data.
Aim & Objective: To present the current considerations, natural history and treatment modalities of cutaneous neurofibromas (cNF)
Methods: Cutaneous Neurofibroma experts from various research and clinical backgrounds reviewed the terms currently in use for cNF as well as the clinical, histologic, and radiographic features of these tumors using available data.
Results: Neurofibromas develop within nerves, soft tissue, and skin. The primary distinction between cNF and other neurofibromas is that cNF are limited to the skin whereas other neurofibromas may involve the skin, but are not limited to the skin. There are important cellular, molecular, histologic, and clinical features of cNF. Each of these factors is discussed in consideration of a clinicopathologic framework for cNF.
Conclusion: The development of various treatment options for neurofibroma requires formulation of diagnostic criteria that encompass the clinical and histologic features of these tumors. However, the rear several areas of overlap between cNF and other neurofibromas that make distinctions between cutaneous and other neurofibromas more difficult, requiring careful deliberation with input across the multiple disciplines that encounter these tumors and ultimately, prospective validation. The ultimate goal of this work is to facilitate accurate diagnosis and meaningful therapeutics for cNF.